Alterity Therapeutics Limited

NASDAQ:ATHE

Biotechnology

Healthcare
$3.12 +9.89%

+$0.53 today

Market cap
$52.77M
Beta
-0.03
P/E (TTM)
-9.9
EPS (TTM)
-$0.07
52W Low $2.66High $7.00

Volume 0.02M

Average 0.05M

ATHE Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Alterity Therapeutics LimitedNASDAQ: ATHE

Gross Profit · Q2 FY2026 · quarter ended Dec 2025

Gross profit turns negative

Q2 FY2026 gross profit was -A$56.83K, compared with A$1.54M a year earlier. Over 3 fiscal years it compounded at +3.7% a year.

Context

  • Gross profit amounted to 97.7% of revenue in FY2025, up 3.0 pp from a year earlier.
  • Gross profit increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
-A$56.83K— QoQ
Last fiscal yearJun 2025
A$5.31M+39.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-103.7%——
1 year+39.6%——
3-year CAGR+3.7%——
5-year CAGR——
10-year CAGR——

Gross Profit history

AUD · from the income statement

Latest · FY2025
5.31M AUD
Year-over-year change
+39.6%
4-year CAGR
+7.5%

Gross Profit vs competitors

How ATHE compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +39.6% is the highest of 2, against a peer median of -53.4%.
  • Gross profit amounts to 97.7% of revenue for ATHE, versus a peer median of 31.3%.
ATHE Competitors
Gross Profit for ATHE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATHEAlterity Therapeutics LimitedFY2025A$5.31M AUD+39.6%+3.7%97.7%
DYAIDyadic International, Inc.LTM Mar 2026$929.95K USD-53.4%—31.3%
MAIAMAIA Biotechnology, Inc.LTM Mar 2026$0 USD———
ANVSAnnovis Bio, Inc.LTM Mar 2026$0 USD———
Peer median (excluding ATHE) —-53.4%—31.3%

Competitors are the stored peer set for ATHE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

AUD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue4.34M5.12M3.92M4.02M5.44M
Cost of Revenue360.03K364.67K285.07K214.3K127.52K
Gross Profit3.98M4.76M3.63M3.8M5.31M
Gross Margin91.7%92.9%92.7%94.7%97.7%
Research & Development12.28M14.75M13.2M18.64M14.4M
Selling, General & Admin6.87M5.51M5.04M4.76M5.48M
Operating Expenses19.16M20.26M18.24M23.41M19.89M
Depreciation & Amortization18.66K54.21K37.85K35.34K28.31K
EBITDA(15.16M)(17.39M)(14.6M)(19.57M)(14.63M)
EBITDA Margin-349.3%-339.5%-372.8%-486.9%-269.0%
Operating Income(15.18M)(15.5M)(14.64M)(19.6M)(14.57M)
Operating Margin-349.8%-302.6%-373.7%-487.7%-268.0%
Interest Income20.68K2.5K16.44K268.42K446.29K
Interest Expense00000
Other Income / Expenses(133.04K)2.72M904.68K524.33K2.49M
Income Before Tax(15.31M)(12.78M)(13.7M)(19.08M)(12.08M)
Pre-Tax Margin-352.8%-249.4%-349.9%-474.6%-222.1%
Income Tax Expense(3.08M)70.01K104.46K46.09K68.06K
Net Income(15.31M)(12.85M)(13.81M)(19.12M)(12.15M)
Net Margin-352.8%-250.7%-352.5%-475.8%-223.4%
EPS (Basic)(5.40)(3.18)(3.42)(3.12)(1.14)
EPS (Diluted)(5.40)(3.18)(3.42)(3.12)(1.14)
Weighted Avg Shares2.83M4.01M4.05M6.08M10.66M
Weighted Avg Shares (Diluted)2.83M4.01M4.05M6.08M10.66M

Alterity Therapeutics Limited

NASDAQ:ATHE

Intrinsic Alpha fair value

Locked

Current Price

$3.12

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.